CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

RosuvastatinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)

Name (Synonyms) Correlation
drug530 COVID positive via testing Wiki 0.71
drug2465 Rosuvastatin + BAY1817080 Wiki 0.71
drug2789 Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) Wiki 0.71
drug2466 Rosuvastatin + BI 1323495 Wiki 0.71
drug825 Dabigatran etexilate + BI 1323495 Wiki 0.71
drug824 Dabigatran etexilate Wiki 0.71

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.13
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.13

There are 2 clinical trials

Clinical Trials

1 Open Label, Fixed Sequences, One-way Cross-over Study to Determine the Effects of Multiple Doses BAY1817080 (150 mg) on the Pharmacokinetics of a 5 mg Dose Rosuvastatin in Healthy Participants

Researchers in this study want to learn how the study drug BAY1817080 interacts with another drug called rosuvastatin (brand name: Crestor) and affects the way the body absorbs, distributes and excretes rosuvastatin in healthy adult male and female participants (drug-drug interaction study). The study drug BAY1817080 is a new drug under development with a goal to suppress pain and chronic cough. It works by binding to and blocking proteins related to pain in the body. Rosuvastatin is an approved and marketed drug to lower high levels of "bad" cholesterol (a waxy, fat-like substance found in blood). Both drugs interact with the same proteins (molecules) in the human body, and as a result, the study drug may affect the way rosuvastatin is taken up and used by the body when applied together. Participants in this study will be asked to visit the clinic 3 times over a period of 3 to 4 weeks. Each participant will receive rosuvastatin tablets twice with at least 11 days in between and the study drug tablets twice daily for 14 days. Blood samples will be taken from the participants to measure the blood levels of rosuvastatin.

NCT04252300 Drug Interactions Drug: Rosuvastatin Drug: Rosuvastatin + BAY1817080

Primary Outcomes

Measure: Maximum plasma concentration of rosuvastatin without concomitant administration of BAY1817080 (Cmax)

Time: Predose and up to 15 hours after drug on Day 1, 0 and 12 hours on Day 2, 0 hours on Day 3, 4 and 5 of Period 1

Measure: Maximum plasma concentration of rosuvastatin after concomitant administration of BAY1817080 (Cmax1)

Time: Predose and up to 15 hours after rosuvastatin on Day 8, 0 and 12 hours on Day 9, 0 hour on Days 10, 11, 12, 13, 14 and 15 of Period 2

Measure: Area under the concentration-time curve of rosuvastatin without concomitant administration of BAY1817080 (AUC)

Time: Predose and up to 15 hours after drug on Day 1, 0 and 12 hours on Day 2, 0 hours on Day 3, 4 and 5 of Period 1

Measure: Area under the concentration-time curve of rosuvastatin after concomitant administration of BAY1817080 (AUC1)

Time: Predose and up to 15 hours after rosuvastatin on Day 8, 0 and 12 hours on Day 9, 0 hour on Days 10, 11, 12, 13, 14 and 15 of Period 2

Secondary Outcomes

Measure: Number of participants with treatment-emergent adverse events (TEAEs)

Time: Up to 10 weeks

Measure: Severity of treatment-emergent adverse events

Time: Up to 10 weeks

2 Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1323495 in Healthy Male Subjects (Open, Single-dose, Randomised, Two-period Crossover Design in Each Trial Part)

The main objectives of this trial are to investigate the relative bioavailabilities of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1323495 (Test 1, Test 2) following oral administration.

NCT04257032 Healthy Drug: Rosuvastatin Drug: Rosuvastatin + BI 1323495 Drug: Dabigatran etexilate Drug: Dabigatran etexilate + BI 1323495

Primary Outcomes

Measure: Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

Time: up to 5 days

Measure: Maximum measured concentration of Rosuvastatin in plasma (Cmax)

Time: up to 5 days

Measure: Area under the concentration-time curve of Dabigatran in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

Time: up to 4 days

Measure: Maximum measured concentration of Dabigatran in plasma (Cmax)

Time: up to 4 days

Secondary Outcomes

Measure: Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

Time: up to 5 days

Measure: Area under the concentration-time curve of Dabigatran in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

Time: up to 4 days

No related HPO nodes (Using clinical trials)